Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This study is planned to compare the clinical efficacy and safety of aerosolized plus
intravenous colistin vs. intravenous colistin as adjunctive therapy for the treatment of
ventilator-associated pneumonia (VAP) due to pandrugs-resistant (PDR) Acinetobacter baumannii
in the neonates.